Press releases

BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges Revenue of $4.8 billion increased 1.5% as reported and...

Single Test on BD MAX™ Molecular Diagnostic System Identifies and Differentiates Multiple Respiratory Infectious Diseases FRANKLIN LAKES, N.J., Feb. 8, 2023 /PRNewswire/ -- BD (Becton, Dickinson...

Execution of BD 2025 Strategy Delivering Consistent and Durable Performance Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis Revenue from base...

Execution of BD 2025 Strategy Driving Consistent Durable Growth Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased 2.3% on a currency-neutral basis Q4...

Diagnostic Research Center Enables Students to Test and Develop Clinical Workflows to Help Shape Laboratory Performance and Patient Outcomes FRANKLIN LAKES, N.J., Sept. 27, 2022 /PRNewswire/ -- BD...

Research Use Only (RUO) assay now globally available for BD MAX™ System FRANKLIN LAKES, N.J., Sept. 26, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global...

BD EffivaxTM Glass Prefillable Syringe Features Enhanced Technology that Builds on Company's Decades of Expertise in the Prefillable Syringe Market and Supports Customers' Manufacturing Needs...

Revenue from continuing operations of $4.6 billion increased 0.7% as reported and 3.8% on currency-neutral basis Revenue from continuing operations driven by base revenue growth of 6.0% as...

Acquisition adds to company's recent growth in high-technology pharmacy solutions and further accelerates the company's commitment to Smart, Connected Care – offering a customizable platform to...

Research Use Only (RUO) assay now available for BD MAX™ System users FRANKLIN LAKES, N.J., July 27, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...